CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer

OBJECTIVES: To evaluate the activity of intravesical mitomycin‐C (MMC) to ablate recurrent low‐risk non‐muscle‐invasive bladder cancer (NMIBC) and assess whether it may enable patients to avoid surgical intervention for treatment of recurrence. PATIENTS AND METHODS: CALIBER is a phase II feasibility...

Descripción completa

Detalles Bibliográficos
Autores principales: Mostafid, A. Hugh, Porta, Nuria, Cresswell, Joanne, Griffiths, Thomas R.L., Kelly, John D., Penegar, Steven R., Davenport, Kim, McGrath, John S., Campain, Nicholas, Cooke, Peter, Masood, Shikohe, Knowles, Margaret A., Feber, Andrew, Knight, Allen, Catto, James W.F., Lewis, Rebecca, Hall, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318672/
https://www.ncbi.nlm.nih.gov/pubmed/32124514
http://dx.doi.org/10.1111/bju.15038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318672/
https://www.ncbi.nlm.nih.gov/pubmed/32124514
http://dx.doi.org/10.1111/bju.15038

Ejemplares similares